Abstract:Abstract The ER-α36 protein is a 36kDa novel splice variant of the full length 66kDa ER-α. ER-α36 lacks both transcriptional activation domains of ER-α66 but retains the DNA-binding domain and partial dimerization and ligand-binding domains. It has been shown that ER-α36 could trigger membrane-initiated signaling in ER-α36 over-expressing 293 cells, suggesting that ER-α36 might have functions linked with activation of intracellular signaling.To further explore the mechanism(s) of ER-α36 activation of intracellular signaling, in particular the possible relationship between ER-α36 and HER2 in breast cancer, we performed a pilot study. First, we examined the correlation between ER-α36 and HER2 by immunohistochemistry (IHC) using a specific anti-ER-α36 antibody designed against a unique epitope located in the C-tail of ER-a36 which is not present in ER-α66. The results showed that the expression of ER-α36 was highly associated with HER2 in a cohort of 249 breast tumors (P<0.05). Then, we examined whether ER-α36 physically interacts with HER2 in breast cancer cell lines using co-immunoprecipitation (Co-IP) and Western blotting (WB) experiments. We found that ER-α36 interacts with HER2 in both MCF7/HER2 and BT474 cell lines. Second, we explored whether ER-α36 influences the activation of HER2 and its downstream signaling by knocking down ER-α36 expression in both MCF7/HER2 and BT474 cell lines. We found that knockdown of ER-α36 by siRNA abrogated the activation of P-HER2, as well as Akt and MAPK, in both MCF7/HER2 and BT474 cells. Finally, we asked the key question whether ER-α36 was associated with cell proliferation/survival. Strikingly, we found that when both MCF7/HER2 and BT474 cells were deprived of ER-α36 by siRNA, they died quickly, whereas control cells grew normally.In conclusion, our preliminary data suggests that there might be a crosstalk between ER-α36 and HER2 signaling, and that this crosstalk might promote tumor cell survival through HER2/Akt and/or HER2/MAPK signaling pathways in breast cancer. Thus, ER-α36 may be a valuable biomarker and a novel therapeutic target in breast cancer. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 2121.

ER-α36, a Novel Variant of Estrogen Receptor Α, is Involved in EGFR-related Carcinogenesis in Endometrial Cancer.

ER-α36: a Novel Biomarker and Potential Therapeutic Target in Breast Cancer.

Expression of ER-α36, a novel variant of estrogen receptor in endometrial carcinoma and its clinical significance.

Expression of ERα36 in gastric cancer samples and their matched normal tissues.

The therapeutic target of estrogen receptor-alpha36 in estrogen-dependent tumors

A Novel Variant of ER-alpha, ER-alpha36 Mediates Testosterone-Stimulated ERK and Akt Activation in Endometrial Cancer Hec1A Cells.

ER-alpha36, a Novel Variant of ER-alpha, is Expressed in ER-positive and -Negative Human Breast Carcinomas.

ER-α36 Promotes the Malignant Progression of Cervical Cancer Mediated by Estrogen via HMGA2

ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways.

Estrogen-independent Effects of ER-α36 in ER-negative Breast Cancer

A Variant of Estrogen Receptor-Alpha, Her-Alpha 36: Transduction of Estrogen- and Antiestrogen-Dependent Membrane-Initiated Mitogenic Signaling

A primary study on the expression of estrogen receptor α36 in endometrial carcinoma tissues

Expression of ER-{alpha}36, a Novel Variant of Estrogen Receptor {alpha}, and Resistance to Tamoxifen Treatment in Breast Cancer.

ERα36 is an Effective Target of Epigallocatechin-3-gallate in Hepatocellular Carcinoma.

A novel variant of estrogen receptor-alpha is expressed in ER-negative breast cancer and mediates membrane-initiated estrogen signaling

Crosstalk Between Estrogen Receptor Alpha 36, A Dominant Extra-Nuclear Er, And Her2 Promotes Tumor Cell Survival In Breast Cancer

Identification, Cloning, and Expression of Human Estrogen Receptor-Α36, a Novel Variant of Human Estrogen Receptor-Α66

Quantitative Profiles of the Mrnas of ER-α and Its Novel Variant ER-α36 in Breast Cancers and Matched Normal Tissues

RETRACTED: Predictive and Prognostic Value of ER-α36 Expression in Breast Cancer Patients Treated with Chemotherapy

Different Biological Effect of Estrogen Receptor-Related Receptor Α in Estrogen Receptor-Positive and -Negative Endometrial Carcinoma.

Estrogen Receptor Alpha Variant Er Alpha 46 Mediates Growth Inhibition and Apoptosis of Human Ht-29 Colon Adenocarcinoma Cells in the Presence of 17 Beta-Oestradiol